Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease
Journal of Allergy and Clinical Immunology · 2023
DOI: 10.1016/j.jaci.2023.03.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023. Verfasst von Hiroaki Hayashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan; Department of…. Hauptthemen laut MEDLINE: Asthma, Aspirin-Induced, Sinusitis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, GlaxoSmithKline Japan, Sanofi.
Abstract (Originalsprache)
BACKGROUND: Omalizumab, an anti-IgE antibody, has clinical efficacy against respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some patients with AERD also present with extrarespiratory (chest, gastrointestinal, and/or cutaneous) symptoms, which are resistant to conventional treatment but can be alleviated by systemic corticosteroids. OBJECTIVE: We evaluated the efficacy of omalizumab on extrarespiratory symptoms related to AERD. METHODS: In study 1, a total of 27 consecutive patients with AERD initially prescribed omalizumab at Sagamihara National Hospital between July 2009 and March 2019 were retrospectively studied. Frequency of exacerbations of AERD-related extrarespiratory symptoms was compared before and after omalizumab treatment. In study 2, we reported 3 AERD cases with aspirin challenge-induced extrarespiratory symptoms among patients studied in our previous randomized trial (registration UMIN000018777), which evaluated the effects of omalizumab on hypersensitivity reactions during aspirin challenge to AERD patients. Extrarespiratory symptoms induced during the aspirin challenge were compared between placebo and omalizumab phases. RESULTS: In study 1, omalizumab treatment was associated with decrease in frequency of exacerbation of chest pain (no. [%] of patients with exacerbation frequency ≥1 time per year, 6 [22.2%] vs 0; P < .001), gastrointestinal symptoms (9 [33.3%] vs 2 [7.4%]; P = .016), and cutaneous symptoms (16 [59.3%] vs 2 [7.4%]; P < .001), even under conditions of treatment-related reduction in systemic corticosteroid dose. Omalizumab also attenuated all the extrarespiratory symptoms during aspirin challenge in study 2. CONCLUSION: Omalizumab ameliorated extrarespiratory symptoms at baseline (without aspirin exposure) and during aspirin challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine,…
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan.
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan; Center for Immunology and Allergology, Shonan Kamakura General Hospital, Kamakura,…
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan; Department of Respiratory Medicine, St Marianna University School of Medicine, Yoko…
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization of Nagoya Medical Center, Nagoya, Japan.
Förderung
- Japan Agency for Medical Research and Development
- GlaxoSmithKline Japan
- Sanofi
Zitieren
APA
Hayashi, H., Fukutomi, Y., Mitsui, C., Kajiwara, K., Watai, K., Tomita, Y., Kamide, Y., Tsuburai, T., Sekiya, K., Ishii, M., Hasegawa, Y., & Taniguchi, M. (2023). Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.03.014
Vancouver
Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Tomita Y, et al. Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. 2023. doi:10.1016/j.jaci.2023.03.014
BibTeX
@article{Hayashi2023,
author = {Hayashi, Hiroaki and Fukutomi, Yuma and Mitsui, Chihiro and Kajiwara, Keiichi and Watai, Kentaro and Tomita, Yasuhiro and Kamide, Yosuke and Tsuburai, Takahiro and Sekiya, Kiyoshi and Ishii, Makoto and Hasegawa, Yoshinori and Taniguchi, Masami},
title = {Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
doi = {10.1016/j.jaci.2023.03.014}
}
EUVIMED